Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael Simons is active.

Publication


Featured researches published by Michael Simons.


Circulation | 2000

Effect of Intracoronary Recombinant Human Vascular Endothelial Growth Factor on Myocardial Perfusion Evidence for a Dose-Dependent Effect

Robert C. Hendel; Timothy D. Henry; Krishna J. Rocha-Singh; Jeffrey M. Isner; Frank J. Giordano; Michael Simons; Robert O. Bonow

BACKGROUNDnAnimal models of therapeutic angiogenesis have stimulated development of clinical application in patients with limited options for coronary revascularization. The impact of recombinant human vascular endothelial growth factor (rhVEGF) on myocardial perfusion in humans has not been reported.nnnMETHODS AND RESULTSnFourteen patients underwent exercise (n=11), dobutamine (n=2), or dipyridamole (n=1) myocardial perfusion single photon emission CT (SPECT) before as well as 30 and 60 days after rhVEGF administration. After uniform processing and display, 2 observers blinded to the timing of the study and dose of rhVEGF reviewed the SPECT images. By a visual, semiquantitative 20-segment scoring method, summed stress scores (SSS) and summed rest scores (SRS) were generated. Although the SSS did not change from baseline to 30 days (21.6 versus 21.5; P=NS), the SRS improved after rhVEGF (13.2 versus 10.4; P<0.05). Stress and rest perfusion improved in >2 segments infrequently in patients treated with low-dose rhVEGF. However, 5 of 6 patients had improvement in >2 segments at rest and stress with the higher rhVEGF doses. Furthermore, although neither the SSS nor the SRS changed in patients treated with the low doses, the SRS decreased in the high-dose rhVEGF patients at 60 days (14.7 versus 10.7; P<0.05). Quantitative analysis was consistent with the visual findings but failed to demonstrate statistical significance.nnnCONCLUSIONSnAlthough not designed to demonstrate rhVEGF efficacy, these phase 1 data support the concept that rhVEGF improves myocardial perfusion at rest and provide evidence of a dose-dependent effect.


American Heart Journal | 1999

Angiographic methods to assess human coronary angiogenesis

C.Michael Gibson; Kathryn Ryan; Anthony Sparano; John Moynihan; Michael Rizzo; Michael P. Kelley; Susan J. Marble; Roger J. Laham; Michael Simons; Theodore R. McClusky; J.Theodore Dodge

It is unclear how agents designed to promote angiogenesis in the human heart affect the arteriographic appearance of the collateral circulation. Possible changes in collateral vessels include new collateral vessels arising from epicardial arteries, new branches emanating from existing collateral vessels, wider or longer collateral vessels, and higher dye transit rates that result in improved recipient vessel filling. Given the multiple mechanisms by which these new agents may improve myocardial perfusion, a rigorous, systematic, and comprehensive analysis of coronary arteriograms is required to discern the true mechanism of benefit. The method of analysis must account for potential changes in collateral blood flow, number, branching pattern, and length as well as changes in recipient vessel filling. The ability to detect differences between intricate networks of vessels in an angiographic study is dependent on maintaining consistency in cinefilming as well as the core laboratory methods between time points. In this report, we describe the methodology our angiographic core laboratory has found to be most effective to evaluate these very complex angiograms and attempt to capture all the possible modalities of angiogenesis.


Catheterization and Cardiovascular Interventions | 1999

Subxyphoid access of the normal pericardium: a novel drug delivery technique.

Roger J. Laham; Michael Simons; David Hung

The pericardial space may potentially serve as a drug delivery reservoir that might be used to deliver therapeutic substances to the heart. This study describes a novel delivery technique that enables safe and rapid percutaneous subxyphoid access of the normal pericardium in a large animal model (49 Yorkshire pigs). An epidural introducer needle (Tuohy‐17) is advanced gently under fluoroscopic guidance with a continuous positive pressure of 20–30 mm Hg (achieved by saline infusion using an intraflow system). The positive pressure is intended to push the right ventricle (with a lower pressure) away from the needles path. Entry of the pericardial space is suspected after an increase in the saline flow through the intraflow system. Access to the pericardial space is confirmed by the injection of 1 ml of diluted contrast under fluoroscopy. A soft floppy‐tip 0.025” guidewire is then advanced to the pericardial space and the needle is exchanged for an infusion catheter. Access of the pericardial space was achieved in all animals without any adverse events and without any hemodynamic compromise even with the delivery of fluid volumes as large as 50 ml. Histologic examination in 15 animals 4 weeks after pericardial access did not reveal any delivery‐related myocardial damage. The safety, ease, and absence of hemodynamic compromise make this technique a potentially useful method for intrapericardial drug delivery and a good alternative to standard pericardiocentesis in patients with small pericardial effusions at higher risk for complications. Cathet. Cardiovasc. Intervent. 47:109–111, 1999.


Archive | 1997

Endogenous Expression Modification: Antisense Approaches

Michael Simons

Antisense approaches provide alternative tools to local modification of gene expression. In this chapter we will consider different antisense techniques, discuss the nature and theoretical basis of this approach, and examine its in vivo application. We will primarily focus on application of antisense techniques to vascular smooth muscle cell studies, but other areas of applications will be mentioned as well.


Circulation | 2000

Clinical Trials in Coronary Angiogenesis: Issues, Problems, Consensus An Expert Panel Summary

Michael Simons; Robert O. Bonow; Nicolas Chronos; David J. Cohen; Frank J. Giordano; H. Kirk Hammond; Roger J. Laham; William W. Li; Marylin Pike; Frank W. Sellke; Thomas J. Stegmann; James E. Udelson; Todd K. Rosengart


Cancer Research | 2000

Anti-angiogenic Cues from Vascular Basement Membrane Collagen

Pablo C. Colorado; Adriana Torre; George D. Kamphaus; Yohei Maeshima; Helmut Hopfer; Keiko Takahashi; Ruediger Volk; Eric D. Zamborsky; Seth Herman; Pradip K. Sarkar; Mark B. Ericksen; Mohanraj Dhanabal; Michael Simons; Mark J. Post; Donald Kufe; Ralph R. Weichselbaum; Vikas P. Sukhatme; Raghu Kalluri


American Heart Journal | 2001

Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease

Timothy D. Henry; Krishna J. Rocha-Singh; Jeffrey M. Isner; Frank J. Giordano; Michael Simons; Douglas W. Losordo; Robert C. Hendel; G. Robert O. Bonow; Stephen Eppler; Thomas F. Zioncheck; Eric Holmgren; Edward R. McCluskey


Clinical Cardiology | 1999

Therapeutic myocardial angiogenesis using percutaneous intrapericardial drug delivery.

Roger J. Laham; David Hung; Michael Simons


Journal of Laboratory and Clinical Medicine | 1996

Therapeutic manipulation of cell cycle in smooth muscle cells: implications for restenosis.

Michael Simons


Japanese Circulation Journal-english Edition | 1996

Antisense Approach to Restenosis

Michael Simons

Collaboration


Dive into the Michael Simons's collaboration.

Top Co-Authors

Avatar

Roger J. Laham

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Donald S. Baim

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Frank W. Sellke

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge